Study Finds that ChromeMate Reduces Vascular Inflammation.

ChromeMate, the patented niacin-bound chromium (Cr polynicotinate), was found to significantly reduce vascular inflammation, according to a recent unpublished study presented at the American Diabetes Association’s 68th Annual Scientific Session, June 6 to 10 in San Francisco. The study was funded by the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH). The eight-week study supplemented 400 mcg of chromium from ChromeMate or chromium picolinate per kg of body weight to the diet of obese Zucker diabetic rats. In comparison to the animal control group, the ChromeMate group experienced significantly lower total cholesterol and triglycerides than the chromium picolinate group. Levels of TNF-a (Tumor necrosis factor-alpha), MCP-1 (Monocyte chemo-attractant protein), and RBP4 (Retinol binding protein 4) were also lower in the ChromeMate group than the control group; the chromium picolinate group did not experience any reduction in those markers. InterHealth Nutraceuticals, manufacturer of ChromeMate, stated that the results of this study continue to confirm a comprehensive body of evidence that demonstrates the cardiovascular benefits of ChromeMate. ChromeMate, a supplement highly effective in helping maintain healthy blood sugar levels and body weight, is important for people with diabetes. Given the close link between diabetes and cardiovascular disease, ChromeMate represents a triple benefit in promoting good health.